Infinity Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INFIQ research report →
Companywww.infi.com
Infinity Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors.
- CEO
- Lawrence E. Bloch
- IPO
- 2000
- Employees
- 30
- HQ
- Cambridge, US
Price Chart
Valuation
- Market Cap
- $9.08K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.22
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 39.72%
- Op Margin
- -1729.43%
- Net Margin
- -1711.11%
- ROE
- -3521.35%
- ROIC
- -154.02%
Growth & Income
- Revenue
- $2.59M · 39.56%
- Net Income
- $-44,369,000 · 1.97%
- EPS
- $-0.50 · 5.66%
- Op Income
- $-44,844,000
- FCF YoY
- -4.48%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 8.79
- Avg Volume
- 54.98K
Get TickerSpark's AI analysis on INFIQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our INFIQ Coverage
We haven't published any research on INFIQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate INFIQ Report →